The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2024 | Monitoring, diagnosing & managing cardiotoxicity in AL amyloidosis
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses the monitoring, diagnosis, and management of cardiotoxicity in light chain (AL) amyloidosis. Close monitoring of cardiac biomarkers, such as NT-proBNP and high-sensitivity troponin, is essential. Adjusting treatment based on these biomarkers and patient functional status may be necessary. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
